Posted by Michael Wonder on 28 Mar 2017
Tesaro won’t reveal price of ovarian cancer drug. But it’ll likely be near $14,000 a month.
28 March 2017 - Zejula’s main rivals cost around $13,700 and $12,600 a month, but Tesaro might be able to justify a higher price.
When Tesaro announced Monday afternoon that the U.S. FDA had approved its ovarian cancer drug, the company said it would wait to announce the drug’s price until Zejula launched, in late April.
But because Zejula is part of a class of cancer drugs called PARP inhibitors, getting a sense of what pricing might be is as easy as looking at its competitors.
The drug will likely cost at least $13,700 a month, or the price of Clovis Oncology's Rubraca, said Wedbush analyst David Nierengarten.
